Back

Silencing TTR: siRNA and antisense in the clinic

28 August 2026 (08:51 - 09:09)
Organised by: Logo
Congress Presentation Part of: Frontiers in amyloid heart disease: from treatment to cure Cardiac Amyloidosis ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Mathew Maurer

Columbia University Irving Medical Centre, New York (United States of America)

4 More presentations in this session

Presentation thumbnail
Why amyloid heart disease became treatable: TTR biology and the therapeutic ladder
Doctor L. Obici (Pavia, IT)
Slides Video
Presentation thumbnail
Diagnosis and the window for cure: imaging, biomarkers, and gene-carrier screening
Doctor E. Gonzalez Lopez (Madrid, ES)
Slides Video
Presentation thumbnail
Clearing deposited amyloid: antibody-based depletion
Doctor P. Garcia-Pavia (Majadahonda, ES)
Slides Video
Presentation thumbnail
Gene editing: can CRISPR cure ATTR?
Doctor J. Gillmore (Greater London, GB)
Slides Video

Access the full session

Session thumbnail
Frontiers in amyloid heart disease: from treatment to cure
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 08:51 CET
You may be interested in
thumbnail
Congress Presentation
Amyloidosis
11 May 2026
thumbnail
Congress Presentation
Update on RNAi therapy in hATTR amyloidosis.
22 May 2022
thumbnail
Congress Presentation
Optimising treatment decisions: the clinical relevance of strength of effect in ATTR-CM
28 August 2026
thumbnail
Congress Session
New targets to enhance survival and outcomes in hATTR amyloidosis
22 May 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources